(2019). Experience with the use of perilesional and intralesional recombinant human epidermal growth factor (nepidermin) in the treatment of patients with chronic venous ulcers.
Chicago Style (17th ed.) CitationExperience with the Use of Perilesional and Intralesional Recombinant Human Epidermal Growth Factor (nepidermin) in the Treatment of Patients with Chronic Venous Ulcers. 2019.
MLA (8th ed.) CitationExperience with the Use of Perilesional and Intralesional Recombinant Human Epidermal Growth Factor (nepidermin) in the Treatment of Patients with Chronic Venous Ulcers. 2019.
Warning: These citations may not always be 100% accurate.